France's Biosimilar Law May Set Trend Inside The EU

Law360, New York (February 18, 2014, 6:26 PM EST) -- Beginning on Jan. 1, 2014, French pharmacists are now legally permitted to substitute a biosimilar for the prescribed (reference) biological medicine, as long as the prescribing physician has not marked the prescription as “nonsubstitutable.” While the details will be defined via the enactment of implementing decrees, under the 2014 Social Security Financing Law ("SSFL"), substitution will be allowed only when initiating a course of treatment, and if the biosimilar belongs to the same group as the prescribed product, known as a “similar biologic group.”

Importantly, the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.